Pancreatic Cancer Research

ResearcherMaastricht UniversityActive in the last 2 years

Merlijn U.J.E. Graus

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3645-1458; OpenAlex author ID A5045605685. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 6 papers

Papers 10

  1. Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. First author DOI 10.1002/cam4.72306↗
  2. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  3. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
  4. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  5. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  6. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. First author DOI 10.1097/j.pain.0000000000004059↗
  7. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  8. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. First author DOI 10.1016/j.ejso.2024.109544↗
  9. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.04.017↗
  10. Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. Co-author DOI 10.3390/cancers15143546↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 10 shared papers, 2023–2026 · strength 2.10
  2. Judith de Vos‐Geelen · 10 shared papers, 2023–2026 · strength 2.10
  3. Marjolein Y.V. Homs · 6 shared papers, 2026 · strength 1.44
  4. Marc G. Besselink · 6 shared papers, 2023–2026 · strength 1.18
  5. Lydia G. van der Geest · 5 shared papers, 2023–2026 · strength 1.04
  6. Ignace H. J. T. de Hingh · 5 shared papers, 2023–2026 · strength 1.03
  7. Aniek E. van Diepen · 4 shared papers, 2025–2026 · strength 0.98
  8. Hanneke W.M. van Laarhoven · 4 shared papers, 2025–2026 · strength 0.89
  9. Stefan A.W. Bouwense · 4 shared papers, 2023–2026 · strength 0.84
  10. Thijmen H.T. Broekman · 3 shared papers, 2026 · strength 0.70
  11. Ruth A.L. Willems · 3 shared papers, 2023–2026 · strength 0.66
  12. Hjalmar C. van Santvoort · 3 shared papers, 2025–2026 · strength 0.58
  13. Lois A. Daamen · 3 shared papers, 2025–2026 · strength 0.55
  14. Izaak Quintus Molenaar · 3 shared papers, 2025–2026 · strength 0.55
  15. Bas Groot Koerkamp · 3 shared papers, 2023–2026 · strength 0.50
  16. Jeanin Elise van Hooft · 2 shared papers, 2026 · strength 0.45
  17. Nick van Es · 2 shared papers, 2023–2026 · strength 0.42
  18. Hugo ten Cate an · 2 shared papers, 2023–2026 · strength 0.42
  19. N C Biesma · 2 shared papers, 2025–2026 · strength 0.40
  20. Vincent Erwin de Meijer · 2 shared papers, 2023–2025 · strength 0.35
  21. Marco J. Bruno · 2 shared papers, 2023–2026 · strength 0.32
  22. Casper W.F. van Eijck · 1 shared paper, 2026 · strength 0.27
  23. Tara M. Mackay · 1 shared paper, 2026 · strength 0.25
  24. Simone Augustinus · 1 shared paper, 2026 · strength 0.24
  25. Pauline A. J. Vissers · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.